PRESATOVIR

/static/temp/default.svg

Search structure


Synonyms	GS-5806 Presatovir
Status
Molecule Category	UNKNOWN
UNII	9628AJ27JA


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	GOFXWTVKPWJNGD-UWJYYQICSA-N
Smiles	Cc1cn2nc([C@@H]3CCCCN3C(=O)c3cc(Cl)ccc3NS(C)(=O)=O)cc2nc1N1CC[C@H](N)C1
InChI	InChI=1S/C24H30ClN7O3S/c1-15-13-32-22(27-23(15)30-10-8-17(26)14-30)12-20(28-32)21-5-3-4-9-31(21)24(33)18-11-16(25)6-7-19(18)29-36(2,34)35/h6-7,11-13,17,21,29H,3-5,8-10,14,26H2,1-2H3/t17-,21-/m0/s1

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C24H30ClN7O3S
Molecular Weight	532.07
AlogP	2.97
Hydrogen Bond Acceptor	8.0
Hydrogen Bond Donor	2.0
Number of Rotational Bond	5.0
Polar Surface Area	125.93
Molecular species	ZWITTERION
Aromatic Rings	3.0
Heavy Atoms	36.0

Bioactivity

Mechanism of Action	Action	Reference
Fusion glycoprotein F0 inhibitor	INHIBITOR	PubMed PubMed PubMed

Targets	EC50(nM)	IC50(nM)	Kd(nM)	Ki(nM)	Inhibition(%)
Surface antigen	0	-	-	-	-

Assay Description	Organism	Bioactivity	Reference
Antiviral activity against Respiratory syncytial virus A2 infected in human Hep2 cells assessed as protection against virus-induced cytopathogenicity after 4 days by cell-Titer Glo assay	Respiratory syncytial virus	0.37 nM
Antiviral activity against Respiratory syncytial virus type A	Respiratory syncytial virus	0.43 nM
Antiviral activity against Respiratory syncytial virus type B	Respiratory syncytial virus	0.43 nM
Antiviral activity against Respiratory syncytial virus clinical isolates	Respiratory syncytial virus	0.1 nM
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of Caco-2 cells at 10 uM after 48 hours by high content imaging	Homo sapiens	22.59 %
Antiviral activity against RSV type B infected in Hep2 cells for 3 days by TMB-ELISA method	Human respiratory syncytial virus	0.43 nM
Antiviral activity against RSV type A infected in Hep2 cells for 3 days by TMB-ELISA method	Human respiratory syncytial virus	0.43 nM
SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate	Severe acute respiratory syndrome coronavirus 2	7.442 %
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging	Chlorocebus sabaeus	0.45 %		Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging	Chlorocebus sabaeus	0.45 %
Inhibition of Human respiratory syncytial virus A2 Fusion protein expressed in Hep2 cells assessed as reduction in virus-induced cytopathic effect after 4 days by Celltiter-Glo viability assay	Human respiratory syncytial virus A2	0.1 nM

Cross References

Resources	Reference
ChEMBL	CHEMBL3410450
DrugBank	DB12165
FDA SRS	9628AJ27JA
PubChem	58029842
SureChEMBL	SCHEMBL2738142
ZINC	ZINC000147513579

CONTENTS

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).